Multiplex methylation marker analysis for ctDNA detection in liquid biopsies from anal cancer patients: an HPV-independent approach
Authors:
Open Access
- 2 July 2026
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 593, 121206
Abstract
No abstract availableKeywords
Funding Information
- Region Syddanmark
This publication has 24 references indexed in Scilit:
- Higher levels of host-cell DNA methylation markers ZNF582 and ASCL1 on anal smears are predictive for progression to anal cancer in patients with previous high-grade lesionsEBioMedicine, 2025
- Development and Validation of an Assay to Quantify Plasma Circulating Tumor Human Papillomavirus DNA for 13 High-Risk Types that Cause 98% of HPV-Positive CancersHead and Neck Pathology, 2025
- Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics AdvancesMolecular Diagnosis & Therapy, 2024
- Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancerTumour Virus Research, 2023
- Condyloma and Anal DysplasiaSurgical Clinics of North America, 2023
- Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus–Associated CancersThe Journal of Molecular Diagnostics, 2023
- Navigating the DNA methylation landscape of cancerTrends in Genetics, 2021
- DNA methylation markers have universal prognostic value for anal cancer risk in HIV‐negative and HIV‐positive individualsMolecular Oncology, 2021
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancerAnnals of Oncology, 2020